Rimonabant
ACOMPLIA
What it isCB1 inverse agonist; obesity. Withdrawn.
Why this oneIt produced weight loss and metabolic benefit by blocking endocannabinoid appetite signaling.
What limits it⚑ Severe depression and suicidality caused withdrawal — the case that showed CB1 blockade cannot be separated from mood.
FDA-approved for
- obesity (withdrawn; never US-approved)
Off-label
- obesity (approved in Europe 2006, withdrawn 2008 for psychiatric harm; never US-approved)
NO BOXED WARNINGS
Principal risk⚑ Severe depression and suicidality caused withdrawal — the case that showed CB1 blockade cannot
Classes and tags
Clinical profile
Mechanism of action: Rimonabant ballicule
